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Background: We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5ml of the CK2-
antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the
recommended dose.
Methods: Fourteen patients were treated with intralesional injections containing 35 or 70mg of CIGB-300 in three alternate cycles
of three consecutive days each before standard chemoradiotherapy. Tumour uptake was determined using 99Tc-radiolabelled
peptide. In situ B23/nucleophosmin was determined by immunohistochemistry.
Results:Maximum tumour uptake for CIGB-300 70-mg dose was significantly higher than the one observed for 35mg: 16.1±8.9 vs
31.3±12.9mg (P¼ 0.01). Both, AUC24h and biological half-life were also significantly higher using 70mg of CIGB-300 (Po0.001).
Unincorporated CIGB-300 diffused rapidly to blood and was mainly distributed towards kidneys, and marginally in liver, lungs,
heart and spleen. There was no DLT and moderate allergic-like reactions were the most common systemic side effect with
strong correlation between unincorporated CIGB-300 and histamine levels in blood. CIGB-300, 70mg, downregulated
B23/nucleophosmin (P¼ 0.03) in tumour specimens.
Conclusion: Intralesional injections of 70mg CIGB-300 in two sites (0.5ml per injection) and this treatment plan are recommended
to be evaluated in phase 2 studies.
The CK2-mediated phosphorylation has a significant role in the
pathogenesis and development of both solid and haematopoietic
tumours (Duncan and Litchfield, 2008; Piazza et al, 2012). Of
note, CK2 signalling pathways seem to reinforce biochemical
cascades indispensable for tumour growth, proliferation and
resistance to conventional and novel cytotoxic agents (Piazza
et al, 2012). Therefore, CK2 inhibition could represent a rational
therapeutic approach to treat both solid and haematological
tumours. In fact, different CK2 inhibitors have already provided
successful proof-of-concept for such rationality at the experi-
mental setting (Ahmada et al, 2005; Prudent et al, 2010;
Siddiqui-Jain et al, 2010) with perspectives to become a novel
cancer-targeted therapeutics in future. Among the CK2 experi-
mental inhibitors, only the CX-4945 small molecule and the
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CIGB-300 cell-permeable peptide have already reached the clinical
stage in phase 1 trials.
The CIGB-300 treatment inhibits the CK2-mediated phosphor-
ylation of the B23/nucleophosmin protein-inducing apoptosis
in vitro and in vivo and halts tumour growth in animals
(Perea et al, 2004, 2008, 2009). Interestingly, it has been
observed that a B23/nucleophosmin downregulation on CIGB-
300-treated tumour cells (Rodriguez-Ulloa et al, 2010) probably is
a consequence of inhibiting the CK2-mediated phosphorylation in
such a protein (Tawfic et al, 1995). Importantly, the CIGB-300
treatment modulates a diverse array of proteins involved in
apoptosis, cell proliferation, ribosomal biogenesis, anti-cancer drug
resistance and angiogenesis in vitro (Rodriguez-Ulloa et al, 2010).
Likewise, evidences of synergistic effect between CIGB-300 and
some standard chemotherapeutics like cisplatin and paclitaxel,
have been also observed both in vitro and in vivo in cervical and
lung cancer models (Perera et al, 2014). Such premises along with
preclinical data demonstrating the significant antitumour activity
of CIGB-300 by intratumour injections in human cervical tumours
(Perea et al, 2008), encouraged the subsequent evaluation of this
peptide-based drug candidate in patients with cervical malignancies
using intralesional injections.
Although the systemic routes are preferred for the administra-
tion of most anti-cancer drugs, we have hypothesised that local
delivery for CIGB-300 could lead to favourable tumour uptake in
patients with relative easy-to-access tumours like those ones in the
uterine cervix. Under this clinical hypothesis, a First-in-Human
trial using CIGB-300 intralesional injections in patients with high-
grade squamous intraepithelial lesions demonstrated to be safe and
tolerable (Solares et al, 2009). In that study, 90% of the patients
experienced a significant colposcopic response, 19% experienced
full histological regression and human papillomavirus DNA was
negative in 48% of the previously positive patients. Furthermore,
CIGB-300 has been also used under compassionate use clauses by
this route. Remarkably, a successful antitumour response was
observed in a chemoradio refractory patient diagnosed with
germinoma who experienced significant tumour shrinking with a
sustained improvement of his quality of life after intratumour
injection of CIGB-300 (Perea et al, 2011).
Finally, a phase 1 trial in patients with cervical cancer FIGO
stages IB2/II using 2ml-intralesional injections of CIGB-300 in
a single site on tumours indicated a plateau in terms of tumour
uptake between doses of 35 and 70mg of the peptide (Soriano-
Garcı´a et al, 2013). Therefore, we hypothesised that less volume
(1ml) applied into two equidistant tumour sites would allow
a greater CIGB-300 tumour uptake using the highest dose, hence
maximising the therapeutic chances for this peptide.
This phase 1 trial was designed to investigate the tumour
uptake, safety profile and pharmacodynamic activity of CIGB-300
injected in two different sites on tumours at 0.5ml per injection.
MATERIALS AND METHODS
Patient selection. Patients histologically diagnosed as FIGO stage
IIB cervical cancer were recruited in five gyneco-obstetric services
in Havana and Matanzas. They were firstly evaluated in the
Reference Center for Cervical Cancer at the ‘Ramo´n Gonza´lez
Coro’ Hospital in Havana, and stage classification was finally
concluded in the gynaecological service of the Center for Medical–
Surgical Research, Havana. CIGB-300 administration and evalua-
tions took place as in-patients in the second institution, except the
first dose when patients were translated to the Clinical Investiga-
tion Center (Havana) for biodistribution/pharmacokinetic studies.
Pre-inclusion evaluation included a detailed history and physical
examination by video colposcopy. In addition, electrocardiogram,
rectoscopy, cystoscopy, haematological counts, blood chemistry,
coagulation and cervix microbiological studies were performed.
Patients were included if they were 18–75-years old, had clinical,
imaging and histological diagnosis of stage IIB cervical epidermoid
carcinoma (Benedet et al, 2003), a WHO general health index from
0 to 2, laboratory parameters within normal limits, and gave their
written informed consent to participate. Exclusion criteria were
chemotherapy or surgical, ablative, radiant, or immunomodulator
treatment in the previous 30 days, psychiatric disease, pregnancy,
breastfeeding, uncontrolled chronic diseases such as diabetes,
hypertension, hepatic or renal chronic insufficiency, epilepsy or
other malignant neoplasia, autoimmune or allergic disease,
coagulation dysfunction, acute systemic infections, current admin-
istration of immunomodulating drugs, tumour extensive necrosis
or genital sepsis that could limit the application of the product, and
participation in another clinical trial in the last 8 weeks.
This trial followed the principles of Good Clinical Practices, in
accordance with the Declaration of Helsinki and its amendments.
The protocol was approved by the Ethic Committees of the
participant institutions, and by the Cuban Regulatory Authority,
the State Center for the Control of Drugs, Equipment & Medical
Devices (CECMED): reference number: 05.009.09.B. Cuban Public
Registry of Clinical Trials: RPCEC00000142.
Study design and treatment plan. A randomised, double-blind,
uncontrolled phase 1 clinical trial was carried out. Patients were
distributed according to a computer-generated random number
list, to receive 35mg (group I) or 70mg (group II) of CIGB-300. It
was expected to include 6–8 patients in each group. This sample
size was inferred starting from a prefixed maximum limit of
toxicity taking into account before experience. That limit was 30%
of patients with grade 3 adverse events into each group, with a 95%
confidence interval. This method for N calculation is considered
specific to pilot studies with transitional therapies even when no
adverse events are registered (Carter and Woolson, 2004).
CIGB-300 was synthesised and supplied by the Peptide
Synthesis Unit at CIGB (Havana) in 35mg vials, as a lyophilised
powder. To keep masking for both groups of patients, the same
number of vials was administered. One CIGB-300 and one placebo
vial were used for the 35mg group and two 35mg vials were used
for 70mg group. Their composition differed only regarding the
presence of CIGB-300. Random lists were kept at the sponsor’s
product-preparation department, where vials were labelled. This
group was independent from the monitors, investigators or other
trial participants. All clinical and laboratory evaluations were
blinded regarding the patients’ group allocation. The code was
opened only in case of serious adverse events, deaths or at the end
of the study, after database closure.
The whole content of the two vials was re-suspended in 1ml
of water for injection, later injected into two equidistant points
(0.5 ml per point) from the lesion centre,B2 cm deep, for 10min
(5min per injection). Injection of necrotic areas with craters or
in the cervical channel was avoided. Patients received three
cycles of CIGB-300 as single agent at weeks 1, 3 and 5. All of
them were hospitalised and treated once daily during three
consecutive days at each cycle. Tumour uptake, whole-
body biodistribution and drug levels in blood were measured
after the first drug administration with 99mTechnetium (Tc)-
labelled CIGB-300. After last cycle (week 5), imaging evaluation
was carried out before conventional chemoradiotherapy. This
regimen consisted in cisplatin 40mgm 2, once per week, during
6 weeks, concomitant to 5040 cGy of external beam radiotherapy
given in 28 fractions, followed by 2600 cGy of intracavitary
radiotherapy given in four high-dose fractions (650 cGy per day)
over 2 weeks. Other interventions were indicated only for the
management of adverse events, according to established clinical
practices.
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Tumour-uptake profile and biodistribution of CIGB-300 in
organs. CIGB-300 was firstly radiolabelled with 99mTc and whole-
body imaging studies were performed at 10min, 1, 2, 4, 8, 12 and
24 h using a gamma camera (Park Medical, Quebec, QC, Canada)
with a high energy collimator for 99mTc. Tumour static views were
also taken at 3 and 24 h. Calculation of the percent of uptaken
radioactivity in tumours and target organs was based on the
Medical Internal Radiation Dose (MIRD) methodology for
quantitative radiopharmaceutical biodistribution data acquisition
(Siegel et al, 1999). Tumour mass was estimated from morpho-
metric data obtained from initial magnetic resonance imaging
(MRI). Biological half-life was adjusted by means of the Microcal
Origin program, version 6.0 (Northampton, MA, USA), taking into
account the radioactive decay. Monoexponential and biexponential
functions were fitted for calculation of the area under the curve.
Pharmacokinetics of CIGB-300. Blood samples were drawn by
venipuncture immediately, 5, 15, 30min and 1, 2, 4, 8, 12 and 24 h
after the first CIGB-300 administration. Subsequently, plasma from
each sample was obtained and CIGB-300 was quantified by an in-
house validated immune competition-based enzyme immunoassay
(EIA). Drug disposition analysis was performed individually by
a non-compartmental method with a combined linear/log–linear
trapezoidal rule approach. All the pharmacokinetic parameters
were determined by using the WinNonlin professional software
(version 5.1, Pharsight Inc., 2005, Princetone, NJ, USA).
Safety evaluation and histamine levels in plasma. Local and
systemic adverse events, including routine laboratory parameters,
were carefully screened up. Systemic toxicity was evaluated during
24 h after each CIGB-300 administration, including cardiovascular
monitoring during the injections and vital signs measurements
(temperature, heart beats, respiration per min and blood pressure).
After chemoradiotherapy, patients were 1-year followed for safety.
The medical terminology for adverse events and their severity
classification (in five grades) was applied according to the
Common Terminology Criteria for Adverse Events (CTCAE)
(2010). The causal relationship was classified as very probable
(definitive), probable, possible or remote (doubtful) (Naranjo et al,
1998).
The CIGB-300-induced histamine levels were measured in
plasma by a commercially available EIA kit (Labor Diagnostika,
GmBH, Oberursel, Germany) before, immediately, 5, 15, 30 and
60min after the first CIGB-300 administration.
Pharmacodynamic activity of CIGB-300 and 1-year clinical
follow-up. Expression of B23/NPM in tumours biopsies was
analysed by immunohistochemistry in paraffin-embedded tumour
biopsies taken before and after CIGB-300 treatment using
a commercial immunostaining kit (Histostain-SP, Zymed Labora-
tories, San Francisco, CA, USA) with a specific human B23/NPM
Mab as primary antibody (Invitrogen, Camarillo, CA, USA).
Deparaffined and further processed biopsies were finally stained
with peroxidase stain and further contrastained with hematoxylin.
Therapeutic response was defined by MRI (Siemens AG,
Erlangen, Germany), according to the RECIST criteria for solid
tumours (Therasse et al, 2000). Images were taken before and after
CIGB-300 treatment and quarterly during a 1-year follow-up after
CIGB-300þ chemoradiotherapy. Computed tomography (CT)
scans (Siemens AG) and abdominal and gynaecological ultrasono-
graphies (Toshiba, Tokyo, Japan) were used to detect proximal and
distant metastasis.
In vivo studies. Female 6–8-week-old NIH nu/nu nude mice were
subcutaneously inoculated with 5 106 of human cervical cancer
SiHa cells into inguinal zone of the right flank. When tumours
reached 150mm3, 100 mg of 99m Tc-radiolabelled CIGB-300 were
intratumour injected in 0.025, 0.05, 0.2 or 0.5ml of PBS. Whole-
body images were collected in living animals immediately after
injection, at 0.25, 1, 4, 24 and 48 h using a planar gamma camera
(Mediso Nucline TH-22, Budapest, Hungary). The region of
interest associated to tumour was selected using the software
ImageJ (1.48r, National Institute of Health, Bethesda, MD, USA)
and results are expressed as percent of total initial image.
The antitumour activity of different CIGB-300 regimens was
explored using a factorial design that combines both number of
cycles of peptide administration (1, 3 or 5 cycles) and the time
interval between each cycle (3, 5 or 8 days). Each cycle consisted of
three consecutive intratumoural injections of 200 mg of CIGB-300.
Tumours were measured with a caliper and the respective volumes
were calculated using the formula: volume¼width2 (mm) length
(mm)/2. Animals were maintained in pathogen-free conditions and
procedures were performed in accordance with recommendations for
the proper use and care of laboratory animals.
Statistical analysis. Continuous variables were expressed as
mean±s.d. or median±quartile range and minimum and
maximum values (range). With these variables, analyses of
normality (Shapiro–Wilk’s test) and homogeneity of variance
(Levene’s test) were carried out. Categorical variables were given as
absolute values and percentages. Biodistribution and pharmacoki-
netic parameters as well as those variables related to the therapeutic
effect were tested by the estimation of the 95% confidence intervals
for the differences between groups as well as the calculation of the
probability that the difference was 40. Tolerability was treated
through the estimation of severe toxicity in both groups. For both
groups the probability to surpass maximum level of toxicity (30%)
was estimated. Spearman rank correlation analyses between
histamine levels and CIGB-300 concentration and between
histamine and severity of the allergic reaction were done. This
test was also used to determine the presence of direct or inverse
correlation accordingly. Immunohistochemical data were treated
using paired analysis (Student’s t-test or Wilcoxon’s test)
depending on the normality assumption.
RESULTS
Patient characteristics and dosing history. Fourteen patients,
seven per dose level, fulfilled the selection criteria to be included in
the trial. Demographic and baseline data are shown in Table 1. The
groups were similar regarding each variable. Most of the patients
were white, their ages ranged from 25 to 61-years old (mean
around 40 years), weighed 50–80 kg and were 152–177 cm tall.
Mean BMI was around 26 kgm 2. All the patients were classified
within stage IIB cervical cancer, and no gynaecological or general
pathological antecedent stood out particularly (data not shown).
Most of the patients completed the three cycles of CIGB-300
treatment, except three of them who discontinued treatment
during the third cycle because of grade 2 allergic syndrome (two
Table 1. Demographic and baseline characteristics
Variable
Group I (35mg),
N¼7
Group II (70mg),
N¼7
Skin colour
White 4 (57.1%) 6 (85.7%)
Non-white 3 (42.9%) 1 (14.3%)
Age (years) 37±8 (25–45) 43±11 (28–61)
Weight (kg) 69±12 (51–84) 64±10 (50–80)
Height (cm) 161±8 (154–177) 157±5 (152–166)
BMI (kgm2) 26.7±6.2 (20.2–35.4) 25.8±3.7 (20.4–31.0)
Cervical cancer stage IIB 7 (100%) 7 (100%)
Abbreviation: BMI¼body mass index. Data are reported as number of patients (%) or
mean±s.d. (range).
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cases, one from each group) and acute febrile disease (one case,
group II). All the patients received at least seven doses of CIGB-300
(median: nine doses). Similarly, all the patients fulfilled the
chemoradiotherapy schedule, except patient no. 2 (group I) who
died because of disease progression.
CIGB-300 tumour-uptake profile and biodistribution. The
time-course analysis of CIGB-300 tumour uptake is shown in
Figure 1. There was a maximum CIGB-300 tumour uptake at
10min after intratumoural administration that gradually decreased
until 24 h in all of the patients. Interestingly, mean value of the
maximum CIGB-300 tumour uptake was near two-fold higher
after injecting 70mg compared with 35mg of CIGB-300 (31.3 vs
16.1mg; P¼ 0.01) (Table 2). After normalising the CIGB-300
tumour uptake respect to tumour mass volume estimated by MRI,
there was roughly 35% increase of this parameter for the group II
respect to group I (1.1±0.8 vs 0.7±0.6mg g 1), although such
difference was not statistically significant (P¼ 0.24) (Table 2).
Importantly, the AUC24 was significantly higher in the group II
respect to group I (385 vs 132mg h; Po0.001) and the CIGB-300
biological half-life was also significantly longer in patients from
group II (6.2±1.9 vs 3.9±0.9 h; Po0.001) (Table 2).
Immediately after the CIGB-300 intratumour injection, the
unincorporated peptide escaped to blood stream and it was mainly
distributed towards kidneys and liver although some radiolabelled
peptide was also detected in lungs, spleen and heart at a lesser
extent (Supplementary Figure 1). Interestingly, in some patients,
CIGB-300 was localised in locoregional nodules and bladder
(data not shown).
Pharmacokinetics of CIGB-300. The pharmacokinetic para-
meters of the unincorporated CIGB-300 after intralesional
injection were estimated from the respective clearance curves in
plasma. The highest CIGB-300 levels in blood were observed only
during the first hour after injection and it was near undetectable
after 8 h for both groups. No significant differences on most of the
pharmacokinetic parameters were detected between both groups,
except for Tmax and t1/2 where they were higher for the group II
(Supplementary Table 2). Interestingly, an inverse correlation
between the CIGB-300 Cmax in blood and the maximum CIGB-300
tumour uptake was observed (P¼ 0.035, r2¼  0.587).
Safety and tolerability. Table 3 lists the local and systemic
toxicities observed during CIGB-300 at both dose levels. Overall,
the type of events were similar in both groups and the allergic-like
reactions were the most common systemic side effect, in particular
hot flashes (100%) and localised itching and rashes (85.7%). A total
of 39 types of adverse events were recorded, 81.7% of the 378
reports corresponded to systemic events and 58.5% occurred in the
group II. Otherwise, only three types of local side effects were
observed being the pain in lower abdomen the most frequent one
(85.7%) in both groups. Only four grade 3 adverse events were
observed in the whole trial irrespective of the CIGB-300 dose level
(Table 3). They were distributed as follows: one allergic reaction,
one anaemia and one tumour bleeding in group I, whereas one
Table 3. Frequency of main local and systemic adverse events
Type of AE
Group I (35mg),
N¼7
Group II (70mg),
N¼7
Local
Pain in lower abdomen 6 (85.7%) 6 (85.7%)
Tumour bleeding 1 (14.3%)a 1 (14.3%)
Genital warm 2 (28.6%) 1 (14.3%)
Systemic
Hot flashes 7 (100%) 7 (100%)
Localised itching 6 (85.7%) 6 (85.7%)
Localised rash 6 (85.7%) 6 (85.7%)
Extensive itching 3 (42.9%) 6 (85.7%)
Hypotension 2 (28.6%) 6 (85.7%)
Tachycardia 3 (42.9%) 5 (71.4%)
Localised bumps 3 (42.9%) 4 (57.1%)
Localised facial oedema 3 (42.9%) 3 (42.9%)
Headache 2 (28.6%) 3 (42.9%)
Nausea 2 (28.6%) 3 (42.9%)
Fever 2 (28.6%) 2 (28.6%)
Localised cramps 2 (28.6%) 2 (28.6%)
Extensive cramps 1 (14.3%) 3 (42.9%)
Dizziness 0 4 (57.1%)
Metallic flavour 1 (14.3%) 3 (42.9%)
Extensive bumps 2 (28.6%) 1 (14.3%)
Extensive rash 2 (28.6%) 1 (14.3%)
Vomiting 2 (28.6%) 1 (14.3%)
Allergic reaction 1 (14.3%)a 1 (14.3%)a
Hypertension 0 2 (28.6%)
Anaemia 1 (14.3%)a 0
aGrade 3 events.
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Figure 1. Time course of CIGB-300 tumour uptake. In the first day of
cycle 1, 35 or 70mg of 99mTc-radiolabelled CIGB-300 was injected
directly into tumours and whole-body gammagraphic images were
taken during 24h after administration. CIGB-300 tumour uptake is
expressed as mg of CIGB-300 retained in tumours. S.e.m. is
represented. Inset corresponds to a illustrative anterior whole-body
image from one patient at 10min after injecting 70mg (group II) of
radiolabelled peptide.
Table 2. CIGB-300 tumour uptake
Parameter Group I (35mg), N¼6a Group II (70mg), N¼7 P (95% CI)
Maximum % ID 46.1±25.7 (10.8–77.7) 44.7±18.4 (14.2–69.6) 0.32 ( 14.1; 33.5)
Maximum uptake (mg CIGB-300) 16.1±8.9 (3.8–27.2) 31.3±12.9 (9.9–48.7) 0.01 (6.3; 27.8)
Maximum uptake (mg CIGB-300 per g tumour) 0.7±0.6 (0.04–1.9) 1.1±0.8 (0.4–2.7)b 0.24 ( 0.8; 1.2)
AUC24 (mgh) 132±72.2 (45.3–235) 385±167 (90.3–646) 0.00 (182; 434)
Biological half-life (h) 3.9±0.9 (2.6–5.5) 6.2±1.9 (3.5–10.1) 0.00 (1.6; 4.4)
Abbreviations: AUC¼ area under curve; CI¼ confidence interval for the differences; ID¼ injected drug. Data are reported as mean±s.d. (range). P: probability that the difference was 40.
aOne patient did not receive the CIGB-300 because of suboptimal radiolabelling.
bN¼ 6 since MRI data were insufficient to estimate tumour mass in one patient.
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allergic reaction was found in group II. The severe allergic
reactions were produced in the last cycle of treatment, otherwise,
anaemia and tumour bleeding was observed after the first cycle.
After red cell transfusion, patient with anaemia recovered normal
haemoglobin values and continued the CIGB-300 treatment
considering the favourable risk–benefit balance. In all the cases,
the allergic reaction events lasted about 15min with further
spontaneous resolution. Cardiovascular events were mostly mild
and had a rapid and spontaneous resolution. The pain in lower
abdomen was successfully treated with analgesics. There were no
differences between baseline and CIGB-300 post-treatment blood
counts and serum chemistry values.
As the transient allergic reactions after CIGB-300 administration
have been associated to the transient histamine induction (Soriano-
Garcı´a et al, 2013), we also verified such biochemical event in this
clinical trial. Figure 2 shows a very similar induction pattern of
plasmatic histamine after the first CIGB-300 injection in both
groups that is characterised by a rapid increase and returning to
normal levels (1 ngml 1) after 15min. Interestingly, a significant
correlation was detected between the histamine levels and the
unincorporated CIGB-300 in blood (Po0.0001) (Supplementary
Table 3). Although there was no significant correlation between the
severity of ‘allergic-like’ events and histamine levels, the overall
histamine median was higher when grade 2 events occurred,
different from grade 1 events: 3.5 vs. 0.7 ngml 1.
Pharmacodynamic activity and therapeutic effect. To explore
pharmacodynamic activity in the CIGB-300 treatment plan
assessed here, we studied the in situ levels of B23/nucleophosmin
in paraffin-embedded tumour biopsies before and after completing
the CIGB-300 therapeutic regimen. Interestingly, CIGB-300
treatment reduced nucleolar B23/NPM expression in 10 out of
the 12 evaluated patients and such suppressive effect was
statistically significant in group II (P¼ 0.03) (Table 4). Otherwise,
B23/nucleophosmin expression at the nucleoplasm was not
considerably modified.
Data from long-term clinical response are shown in Table 5.
Importantly, during 1-year follow-up after chemoradiotherapy, a
better and faster clinical response was observed in those patients
from group II according to the RECIST criteria. Complete response
was achieved in 6 out of 7 patients by the third month in this
group, whereas only 2 out of 6 was observed in group I.
Interestingly, by the sixth month and thereafter, 100% of the
patients exhibited complete response in group II whereas in group
I, three patients did not respond completely, two of them died
(Table 5). Overall, there were four deaths in this clinical trial
because of disease progression, but three of them corresponded to
the group I. There were not new adverse events during 1-year
follow-up. Longer follow-up is currently ongoing and no other
deaths are recorded.
In vivo preclinical studies. To verify how much the injection
volume could influence the tumour uptake, we injected a fixed
99mTc-radiolabelled CIGB-300 dose in 0.025, 0.05, 0.2 or 0.5ml of
PBS in cervical cancer tumours xenografted in nude mice. The
injections in lowest volumes (0.025 and 0.05) exhibited the highest
CIGB-300 tumour uptake, both immediately after application and
thereafter (Figure 3A). Otherwise, higher injection volume
exhibited worse tumour uptake.
We also investigated the number of CIGB-300 cycles required to
achieve a significant antitumour effect, as well as the time interval
required between each cycle, we performed a factorial designed
testing 1, 3 or 5 cycles of peptide administration with drug holidays
of 3, 5 or 8 days between each cycle. Data indicated a comparable
or ‘saturable’ antitumour effect for 3 and 5 cycles of CIGB-300
irrespectively of the timing among each cycle (Figure 3B). Therefore,
three cycles consisting of three consecutive daily injections seem to
be the minimal frequency required to reduce tumour growth by
CIGB-300 administration (Figure 3B).
DISCUSSION
Data from this clinical trial delineate a new optimised protocol for
the CIGB-300 intralesional administration in women with cervical
cancer stage IIB before standard chemoradiotherapy. The injection
of CIGB-300 70mg (in 1ml) in two different sites equidistantly
from the tumour centre (0.5ml per injection) guarantees the
best tumour-uptake profile. It means, better tumour uptake
(31.3±12.9mg), AUC24 (385±167mg h; Po0.001) and t1/2
(6.2±1.9 h) compared with injection of CIGB-300 35mg. How-
ever, the variable baseline tumour size along with relative low
number of patients in each group could influence the limited
increase of the CIGB-300 tumour uptake for 70mg respect to
35mg when correcting it by the estimated tumour mass.
Opposite to these findings, former data injecting 2ml of CIGB-
300 at a single tumour site showed lower and not different
maximum tumour-uptake levels between 35 and 70mg of CIGB-
300 (14.9±6.4 vs 10.4±8.3mg) (Soriano-Garcı´a et al, 2013).
Therefore, besides number of applications, the injection volume
itself could negatively influence on the tumour-uptake profile.
Otherwise, lower volume could favour higher intratumoural CIGB-
300 concentration with minor escape to the vascular and lymphatic
vessels. This hypothesis was concurrently verified here in
preclinical assays where an inverse relation between injection
volume and the CIGB-300 tumour uptake was observed in cervical
cancer tumours xenografted in nude mice. Furthermore, the
injection in two equidistant tumour sites could decrease the risk of
delivery into a necrosis area and permit homogeneous tumour
uptake.
Consistently, after intralesional injection, the unincorporated
CIGB-300 escaped rapidly into blood stream and distributed in
kidneys and liver although some accumulation was also detected in
lungs, heart and spleen in some patients. Interestingly, an inverse
correlation between Cmax of unincorporated CIGB-300 and the
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Figure 2. Plasmatic histamine levels after the first CIGB-300
intratumour injection. Data correspond to the histamine mean values
from patients who received 35mg (solid line, N¼7) or 70mg (dashed
line, N¼ 7) of CIGB-300. Standard deviations are not shown for
simplifying the illustration.
Table 4. Levels of in situ B23/NPM in tumour biopsies
Tumour samples
Group I (35mg),
N¼6
Group II (70mg),
N¼6
Baseline 56.0±17.6 52.8±15.1
Post CIGB-300 36.4±18.9 46.0±14.7
Student’s t-test (p) 0.14 0.03
Data are reported as mean±s.d.
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maximum CIGB-300 tumour uptake was observed. It means,
patients who exhibited higher CIGB-300 tumour uptake had lower
plasmatic concentrations of this peptide, and vice versa.
The rationale of using the CIGB-300 regimen investigated in
this clinical trial was encouraged and supported by data from a
factorial design performed in preclinical studies which indicated
that three cycles of three consecutive daily injections was quite
enough to halt tumour growth in cervical–uterine tumour-bearing
nude mice. Importantly, such CIGB-300 regimen was safe and well
tolerated in patients with locally advanced cervical cancer as
evidenced in this clinical trial. In fact, it was not MTD as grade 3
adverse events did not surpass the limit of toxicity (30% of patients
in any group). However, CIGB-300 70mg had been reported as
MTD in a previous clinical study when intralesional injections
were applied in a different administration regimen (Soriano-Garcı´a
et al, 2013). In this clinical trial only two grade 3 systemic ‘allergic-
like’ (one in each group) events were recorded during treatment
and the onset of allergic reactions paralleled with the CIGB-300
Cmax in blood which in turn, correlated with plasmatic histamine.
Altogether, the CIGB-300 regimen based in three cycles of three
consecutive day injections seemed to be the minimal intervention
required to induce antitumour effect in vivo, it was safe in patients
and therefore, merits to be assayed in phase 2 clinical trials.
In vitro studies have revealed that CIGB-300 impairs the CK2-
mediated phosphorylation on B23/NPM with subsequent induc-
tion of nucleolar disassembly and apoptosis (Perera et al, 2009);
and degradation of B23/NPM on CIGB-300-treated cells has been
documented in non-small cell lung cancer cells (Rodriguez-Ulloa
et al, 2010). Likewise, the B23/NPM downregulation in patients
with cervical cancer treated with CIGB-300 has been previously
observed (Soriano-Garcı´a et al, 2013). Data from this clinical trial
confirm that B23/NPM levels can be modulated by CIGB-300
intralesional injections as observed in 10 out of the 12 evaluated
patients. Interestingly, there was a dose-dependent reduction on
nucleolar B23/NPM expression in tumour biopsies that was
significantly higher in the group treated with CIGB-300 70mg.
Such a finding agrees with the higher CIGB-300 tumour uptake
observed in the group of patients treated with CIGB-300 70mg.
Therefore, the in situ B23/NPM expression meets potentialities as a
feasible response biomarker for CIGB-300 and merits being further
validated in clinical trials designed to explore efficacy of CIGB-300.
Besides the CIGB-300 tumour-uptake profile, safety and
pharmacodynamics, this phase 1 clinical study also permitted to
explore efficacy signs after combining CIGB-300 with chemor-
adiotherapy. Interestingly, during 1-year follow-up, a sustained
clinical response was mainly observed in those patients that
initially received 70mg of CIGB-300 as determined by the number
of patients with complete response according to the RECIST
criteria.
In conclusion, this clinical trial provides a safe and feasible
protocol for the intralesional administration of CIGB-300 where
70mg is the dose with better risk–benefit balance alone and in
combination with chemoradiotherapy. The favourable toxicity
profile along with the efficacy signs could support further phase
2–3 clinical trials in high-risk cervical cancer, particularly in stage
IIB–IVA patients with positive nodes and/or those with poor
tolerance/response to radiotherapy.
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Figure 3. In vivo preclinical studies. (A) CIGB-300 tumour uptake with
different injection volumes. Intratumour injections of 100 mg of 99Tc-
radiolabelled CIGB-300 in 0.025, 0.05, 0.2 or 0.5ml of PBS were
performed in SiHa tumour-bearing nude mice. Whole-body images
were collected in living animals immediately after injection and at 0.25,
1, 4, 24 and 48 h. Data are expressed as percent of total initial image in
different times. Inset corresponds to an example of the initial uptake on
each injection volume tested. (B) Antitumour activity of CIGB-300 in
animal model. The antitumour activity of different CIGB-300 regimens
was explored using a factorial design. CIGB-300 (200mg) was
intratumor injected during 3-, 5- or 8-consecutive days. Concurrently,
1, 3 or 5 cycles of 3-consecutive day injections were investigated.
Tumour mass volume is plotted at different times. Insert corresponds to
the tumour mass volume at day 42.
Table 5. Clinical response during 1-year follow-up
Month 3 Month 6 Month 9 Month 12
Dose group CR PR SD NR CR PR NR CR PR NR CR PR NR
35mg (N¼ 6)a 2 0 3 1b 3 1 2b 3 0 3b 3 0 3
70mg (N¼ 7) 6 1 0 0 7 0 0 7 0 0 6 0 1b
Abbreviations: CR¼ complete response; NR¼ no response; PR¼partial response; SD¼ stable disease.
aImaging studies could not be done in one patient.
bDeaths.
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APPENDIX
The CERVIFARM-300-II Study Group are: Josue´ de la Torre-
Pupo, Mauricio Catala´-Ferrer, Manuel Rodrı´guez-Molina, Emi
Herna´ndez-Ferna´ndez, Belkis Herrera-Pa´ez, Anay Miranda-Fe´lix,
Yolanda Cruz-Go´mez, Ivo´n Howland-A´lvarez, Katia
Aroche-Estalella (Center for Medical-Surgical Research), Elsa M
Masquida-Garcı´a, Elvia Sa´nchez-Mendoza, Marilı´n G Pe´rez-Valde´s
(Clinical Investigation Center), Zaida Barbo´n-Gasso´ (‘Ramo´n
Gonza´lez Coro’ Hospital), Luis S Quevedo-Sotolongo (Central
Clinic ‘Cira Garcı´a’, Havana), Juan M Silveira-Pablos (National
Institute of Oncology, Havana), Jose´ R Mendoza-Montpelier (‘Julio
R Alfonso’ Hospital, Matanzas), Ileana Gutie´rrez (‘Enrique
Cabrera’ Hospital, Havana), Alieski Cruz-Pereira, Jose´ Sua´rez-
Alba, Yaleisys Rosales-Pantoja, Ivette Raı´ces-Cruz, Leovaldo
A´lvarez-Falco´n, Cimara Bermu´dez-Badell (CIGB).
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